- Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
- Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
- Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
- Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
- Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
- Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
- Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
- Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
- Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
- Foghorn Therapeutics Announces CFO Departure
More ▼
Key statistics
On Thursday, Foghorn Therapeutics Inc. (FHTX:NMQ) closed at 5.23, 93.70% above the 52 week low of 2.70 set on Feb 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.04 |
---|---|
High | 5.31 |
Low | 4.80 |
Bid | 5.18 |
Offer | 5.41 |
Previous close | 5.21 |
Average volume | 91.55k |
---|---|
Shares outstanding | 42.57m |
Free float | 32.01m |
P/E (TTM) | -- |
Market cap | 222.62m USD |
EPS (TTM) | -2.35 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 21:00 BST.
More ▼